Trial
NCT02309515
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Mayo Clinic
Collaborators
National Cancer Institute (NCI)
Condition
Monoclonal B-Cell Lymphocytosis
Intervention
Laboratory Biomarker Analysis
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-19